Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer – a propensity score matched analysis
- Conditions
- C25Malignant neoplasm of pancreas
- Registration Number
- DRKS00021765
- Lead Sponsor
- Klinikum der Universität München AVT Chirurgie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 82
Patients undergoing pancreatic surgery at our institution between 01/2014 and 11/2016 .
Inclusion criteria were: (1) confirmed diagnosis of pancreatic ductal adenocarcinoma (PDAC) by pathology, (2) exclusion of distant metastasis at time of surgery, (3) successful resection of primary tumor with curative intent, (4) postoperative survival and/or follow-up of at least 12 weeks, (5) disease-free survival of at least 6 weeks. Since we wanted to focus our analysis on the metastases that might be favored by the perioperative period, we excluded patients who developed metastases within the first 6 weeks after resection, as these must have presumably already existed at the time of surgery.
Patients with diagnosis other than PDAC were excluded as well as patients that suffered from locally advanced disease that underwent neoadjuvant therapy.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.